Table 1.
Demographic and clinical characteristics of patients with chronic hepatitis C
| Patient no. | Sex | Age | HCV GT* | Baseline HCV-RNA (copies/ml) | 4 weeks HCV-RNA (copies/ml) | 4-weeks response* | 12 weeks HCV-RNA (copies/ml) | 12-weeks response | Ribavirin (mg) | Weight, (Kg) | Type of peg IFN | AST | ALT | FOLLOW-UP |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | F | 62 | 2a/2c | 8224917 | NEG | R | NEG | R | 800 | 70 | Alfa 2a | 28 | 31 | SVR |
| 2 | F | 69 | 2 | 19948356 | NEG | R | NEG | R | 1000 | 78 | Alfa 2a | 28 | 30 | SVR |
| 3 | F | 39 | 2c | 2748250 | NEG | R | NEG | R | 800 | 64 | alfa 2a | 30 | 38 | SVR |
| 4 | F | 51 | 2a/2c | 4486254 | NEG | R | NEG | R | 1000 | 68 | Alfa 2a | 17 | 24 | SVR |
| 5 | M | 47 | 1b | 1573026 | 6800 | NR | NEG | R | 1200 | 82 | Alfa 2a | 49 | 68 | SVR |
| 6 | M | 67 | 1a | 6018477 | 21700 | NR | NEG | R | 1000 | 78 | Alfa 2a | 137 | 214 | SVR |
| 7 | F | 68 | 1b | 941010 | NEG | R | NEG | R | 1000 | 74 | Alfa 2a | 25 | 54 | SVR |
| 8 | M | 47 | 2a/2c | 3347068 | 445000 | NR | 937560 | NR | 1000 | 80 | Alfa 2b | 93 | 172 | NR |
| 9 | M | 49 | 2a | 2859813 | 437000 | NR | 378000 | NR | 1000 | 84 | Alfa 2b | 110 | 115 | NR |
| 10 | F | 44 | 1a | 2505703 | 17500 | NR | 327000 | NR | 1200 | 68 | Alfa 2a | 23 | 26 | NR |
| 11 | F | 66 | 1b | 21967894 | 1200000 | NR | 2550 | NR | 800 | 51 | Alfa 2a | 44 | 80 | NR |
| 12 | F | 42 | 1a | 1469947 | 161000 | NR | 16100 | NR | 1000 | 72 | Alfa 2b | 73 | 110 | NR |
*GT, genotype; R, responder, SVR, sustained viral responder; NR, non-responder; IFN, interferon; HCV, hepatitis C virus; AST, aspartate aminotransferase; ALT, alanine aminotransferase.